<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39460341</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Reply to Volkman et al. Comment on "Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. <i>Vaccines</i> 2024, <i>12</i>, 434".</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1175</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines12101175</ELocationID><Abstract><AbstractText>In their comment [...].</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kohli</LastName><ForeName>Michele</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6032-9356</Identifier><AffiliationInfo><Affiliation>Quadrant Health Economics Inc., 92 Cottonwood Crescent, Cambridge, ON N1T 2J1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Keya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Moderna, Inc., 325 Binney Street, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>Ekkehard</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-2022-9190</Identifier><AffiliationInfo><Affiliation>Moderna, Inc., 325 Binney Street, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagiwara</LastName><ForeName>Yuriko</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3754-8278</Identifier><AffiliationInfo><Affiliation>Moderna, Inc., 4-1-1 Toranomon, Kamiyacho, Minato Ward, Tokyo 105-6923, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van de Velde</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Moderna, Inc., 325 Binney Street, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Igarashi</LastName><ForeName>Ataru</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Vaccines (Basel). 12:1174.</RefSource></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Japan</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">cost-effectiveness</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>M.K. is a shareholder in Quadrant Health Economics Inc., which was contracted by Moderna, Inc. to conduct this study. E.B., Y.H., K.J. and N.v.d.V. are employed by Moderna, Inc. and hold stock/stock options in the company. A.I. has received honorarium or research consultation fees from Moderna Inc., Pfizer Inc., Takeda Pharmaceuticals Inc., Shionogi Co., Ltd., and AstraZeneca Japan Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39460341</ArticleId><ArticleId IdType="pmc">PMC11511137</ArticleId><ArticleId IdType="doi">10.3390/vaccines12101175</ArticleId><ArticleId IdType="pii">vaccines12101175</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Volkman H.R., Nguyen J.L., Mustapha M.M., Jodar L., McLaughlin J.M. Comment on Fust et al. The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan. Vaccines 2024, 12, 434. Vaccines. 2024;12:1174. doi: 10.3390/vaccines12101174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12101174</ArticleId><ArticleId IdType="pmc">PMC11054439</ArticleId><ArticleId IdType="pubmed">38675816</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda H. Effectiveness of COVID-19 Vaccines in Japan (VERSUS Study), Tokyo, Japan, 2023.  [(accessed on 25 May 2023)].  Available online:  http://jaid97-jsc71.umin.jp/index.html.</Citation></Reference><Reference><Citation>Kopel H., Nguyen V.H., Boileau C., Bogdanov A., Winer I., Ducruet T., Zeng N., Bonafede M., Esposito D.B., Martin D., et al. Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults. Vaccines. 2023;11:1711. doi: 10.3390/vaccines11111711.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11111711</ArticleId><ArticleId IdType="pmc">PMC10675676</ArticleId><ArticleId IdType="pubmed">38006043</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Stepien S., Qian J., Gidding H., Nicolopoulos K., Amin J., Cheng A., Macartney K. Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection. Vaccine. 2023;41:5587–5591. doi: 10.1016/j.vaccine.2023.07.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.07.050</ArticleId><ArticleId IdType="pubmed">37524631</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvez J.M., Pinzon-Rondon A.M., Chaparro-Solano H.M., Tovar-Romero H.V., Ramirez-Prieto J., Ortigoza-Espitia S.A., Ruiz-Sternberg A.M. Effectiveness of the Booster Dose in Protecting against COVID-19, Colombia 2022. Vaccines. 2023;11:1461. doi: 10.3390/vaccines11091461.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11091461</ArticleId><ArticleId IdType="pmc">PMC10538081</ArticleId><ArticleId IdType="pubmed">37766137</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin E.T., Leidner D., Lamson L., Lucas K., Studdert D.M., Goldhaber-Fiebert J.D., Andrews J.R., Salomon J.A. Protection against Omicron from Vaccination and Previous Infection in a Prison System. N. Engl. J. Med. 2022;387:1770–1782. doi: 10.1056/NEJMoa2207082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2207082</ArticleId><ArticleId IdType="pmc">PMC9634863</ArticleId><ArticleId IdType="pubmed">36286260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk B., Bush C., Toyip A., Mues K.E., Beck E., Li L., St. Laurent S., Georgieva M., Marks M.A., Sun T., et al. Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥65 years in the United States. medRxiv. 2023;11:23298054. doi: 10.1101/2023.11.03.23298054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.11.03.23298054</ArticleId><ArticleId IdType="pubmed">39030080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono S., Michihata N., Yamana H., Uemura K., Ono Y., Jo T., Yasunaga H. Comparative Effectiveness of BNT162b2 and mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Registries in Japan. Clin. Infect. Dis. 2023;76:18–24. doi: 10.1093/cid/ciac763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac763</ArticleId><ArticleId IdType="pmc">PMC9494390</ArticleId><ArticleId IdType="pubmed">36124762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavikondala S., Haeussler K., Wang X., Bausch-Jurken M.T., Nassim M., Mishra N.K., Malmenas M., Sharma P., Van de Velde N., Green N., et al. Comparative Effectiveness of mRNA-1273 and BNT162b2 COVID-19 Vaccines among Older Adults: Systematic Literature Review and Meta-Analysis Using the GRADE Framework. Infect. Dis. Ther. 2024;13:779–811. doi: 10.1007/s40121-024-00936-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-024-00936-z</ArticleId><ArticleId IdType="pmc">PMC11058186</ArticleId><ArticleId IdType="pubmed">38498109</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Haeussler K., Spellman A., Phillips L.E., Ramiller A., Bausch-Jurken M.T., Sharma P., Krivelyova A., Vats S., Van de Velde N. Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: A systematic review and meta-analysis using the GRADE framework. Front. Immunol. 2023;14:1204831. doi: 10.3389/fimmu.2023.1204831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1204831</ArticleId><ArticleId IdType="pmc">PMC10523015</ArticleId><ArticleId IdType="pubmed">37771594</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk B., Bush C., Toyip A., Mues K.E., Beck E., Li L., St. Laurent S., Georgieva M., Marks M.A., Sun T., et al. Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥65 years in the United States. Vaccine. 2024;42:126113. doi: 10.1016/j.vaccine.2024.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.07.014</ArticleId><ArticleId IdType="pubmed">39030080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli M., Maschio M., Lee A., Igarashi A. Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine. Vaccine. 2024;42:2282–2289. doi: 10.1016/j.vaccine.2024.01.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.01.093</ArticleId><ArticleId IdType="pubmed">38429154</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitman R., Fisman D., Zaric G.S., Postma M., Kretzschmar M., Edmunds J., Brisson M., ISPOR-SMDM Modeling Good Research Practices Task Force Dynamic transmission modeling: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5. Value Health. 2012;15:828–834. doi: 10.1016/j.jval.2012.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2012.06.011</ArticleId><ArticleId IdType="pmc">PMC7110742</ArticleId><ArticleId IdType="pubmed">22999132</ArticleId></ArticleIdList></Reference><Reference><Citation>Core2 Health . Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council. Center for Outcomes and Economic Evaluation for Health, National Institute of Public Health; Saitama, Japan: 2022. version 3.0.</Citation></Reference><Reference><Citation>Shiroiwa T., Fukuda T., Ikeda S., Takura T., Moriwaki K. Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan. Value Health. 2017;20:372–378. doi: 10.1016/j.jval.2016.08.726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2016.08.726</ArticleId><ArticleId IdType="pubmed">28292481</ArticleId></ArticleIdList></Reference><Reference><Citation>Akazawa M., Yongue J., Ikeda S., Satoh T. Considering economic analyses in the revision of the preventive vaccination law: A new direction for health policy-making in Japan? Health Policy. 2014;118:127–134. doi: 10.1016/j.healthpol.2014.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healthpol.2014.07.016</ArticleId><ArticleId IdType="pubmed">25139708</ArticleId></ArticleIdList></Reference><Reference><Citation>Akazawa M. Health economic consideration of vaccine effectiveness. Nihon Naika Gakkai Zasshi. 2015;104:2343–2350. doi: 10.2169/naika.104.2343.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/naika.104.2343</ArticleId><ArticleId IdType="pubmed">28530350</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Infections Disease in Japan  Nonoavalent HPV Vaccine Factsheet 2023.  [(accessed on 5 August 2024)].  Available online:  https://www.mhlw.go.jp/content/10906000/000770615.pdf.</Citation></Reference><Reference><Citation>Klein N. Rapid Cycle Analysis to Monitor the Safety of COVID-19 Vaccines in Near Real-Time within the Vaccine Safety Datalink: Myocarditis and Anaphylaxis. Presentation to the Advisory Committee on Immunization Practices.  [(accessed on 15 January 2024)];2021 August 30; Available online:  https://stacks.cdc.gov/view/cdc/109493.</Citation></Reference><Reference><Citation>Shimabukuro T. Update on Myocarditis Following mRNA COVID-19 Vaccination. Presentation to the Vaccines and Related Biological Products Advisory Committee.  [(accessed on 7 June 2022)]; Available online:  https://www.fda.gov/media/159007/download.</Citation></Reference><Reference><Citation>Huang Y., Feng S., Zhao Y., Wang H., Jiang H. Preferences for COVID-19 Vaccines: Systematic Literature Review of Discrete Choice Experiments. JMIR Public Health Surveill. 2024;10:e56546. doi: 10.2196/56546.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/56546</ArticleId><ArticleId IdType="pmc">PMC11319885</ArticleId><ArticleId IdType="pubmed">39073875</ArticleId></ArticleIdList></Reference><Reference><Citation>Igarashi A., Nakano Y., Yoneyama-Hirozane M. Public preferences and willingness to accept a hypothetical vaccine to prevent a pandemic in Japan: A conjoint analysis. Expert Rev. Vaccines. 2022;21:241–248. doi: 10.1080/14760584.2022.2016402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2022.2016402</ArticleId><ArticleId IdType="pubmed">35073824</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>